Daunorubicin

Generic Name
Daunorubicin
Brand Names
Cerubidine, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C27H29NO10
CAS Number
20830-81-3
Unique Ingredient Identifier
ZS7284E0ZP
Background

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.

Indication

For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
Associated Therapies
-
Clinical Trials
Related News

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

First Posted Date
2014-03-12
Last Posted Date
2024-12-13
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
727
Registration Number
NCT02085408
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States

and more 266 locations

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

First Posted Date
2014-01-23
Last Posted Date
2022-05-02
Lead Sponsor
University of California, San Diego
Target Recruit Count
31
Registration Number
NCT02043587
Locations
🇺🇸

UCSD, Division of Blood and Marrow Transplantation, Moores Cancer Center, La Jolla, California, United States

🇺🇸

Hematological Malignancies/Stem Cell Transplantation Unit, David Geffen School of Medicine at UCLA, Los Angeles, California, United States

🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 1 locations

A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

First Posted Date
2014-01-17
Last Posted Date
2024-01-12
Lead Sponsor
Pfizer
Target Recruit Count
48
Registration Number
NCT02038777
Locations
🇯🇵

Japanese Red Cross Nagoya First Hospital, Nagoya, Aichi, Japan

🇯🇵

Kobe University Hospital, Kobe-shi, Hyogo, Japan

🇯🇵

Akita University Hospital, Akita, Japan

and more 6 locations

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

First Posted Date
2014-01-15
Last Posted Date
2020-03-05
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
107
Registration Number
NCT02036489
Locations
🇪🇸

Hospital Germans Trias i Pujol, Barcelona, Spain

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

First Posted Date
2013-12-17
Last Posted Date
2024-02-23
Lead Sponsor
University of Ulm
Target Recruit Count
204
Registration Number
NCT02013648
Locations
🇦🇹

Hanuschkrankenhaus, Wien, Austria

🇦🇹

Krankenhaus der Barmherzigen Schwestern, Linz, Austria

🇦🇹

Universitätsklinik der PMU, Salzburg, Austria

and more 51 locations

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

First Posted Date
2013-12-06
Last Posted Date
2024-12-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
488
Registration Number
NCT02003222
Locations
🇺🇸

Banner North Colorado Medical Center, Greeley, Colorado, United States

🇺🇸

Good Samaritan Hospital - Cancer Centers of Colorado, Lafayette, Colorado, United States

🇺🇸

Banner McKee Medical Center, Loveland, Colorado, United States

and more 545 locations

Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients

First Posted Date
2013-12-03
Last Posted Date
2018-04-27
Lead Sponsor
French Innovative Leukemia Organisation
Target Recruit Count
30
Registration Number
NCT01999413
Locations
🇫🇷

Emmanuel GYAN, Tours, France

Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008

First Posted Date
2013-10-01
Last Posted Date
2020-02-05
Lead Sponsor
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Target Recruit Count
3000
Registration Number
NCT01953770
Locations
🇺🇿

Research Institute of Hematology and Blood Transfusion, Tashkent, Uzbekistan

🇷🇺

Republic Hospital №1 - National Medicine Centre, Yakutsk, Russian Federation

🇧🇾

Republican Research and Practical Center of Radiation Medicine, Gomel, Belarus

and more 36 locations

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

First Posted Date
2013-08-12
Last Posted Date
2023-10-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
39
Registration Number
NCT01920737
Locations
🇺🇸

Weill Cornell Medical Center, New York, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

First Posted Date
2013-07-02
Last Posted Date
2019-09-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
148
Registration Number
NCT01890746
Locations
🇷🇺

Novartis Investigative Site, Tula, Russian Federation

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy